News

Biosimilars Market Worth US$72.29 Billion By 2035 With 7.5% CAGR Marketsandmarketstm
We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...
Healio2d
Latest from FDA: Zoryve foam, more psoriasis biosimilars, Keytruda for skin cancer
Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...
The Manila Times1d
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...
pharmaphorum1d
First biosimilar fast-acting insulin reaches US market
It is the first biosimilar of a rapid-acting insulin product – used to control the blood glucose spike after meals – and only the third insulin biosimilar to be approved in the US.
pharmaphorum2d
FDA clears Amgen’s Bkemv as first biosimilar of Soliris
Amgen’s Bkemv is first FDA-approved biosimilar to AstraZeneca’s Soliris in the US, getting interchangeable status for rare diseases PNH and aHUS.
Nature5d
Biosimilars: the impact of their heterogeneity on regulatory approval - Nature
Online Correspondence Published: March 2007 Biosimilars: the impact of their heterogeneity on regulatory approval Asterios S Tsiftsoglou Nature Reviews Drug Discovery 6, 252 (2007) Cite this article ...